The pharmaceuticals company Glenmark Pharma Ltd introduce medicine for the time with the combination of  Teneligliptin (20mg) and Dapagliflozin (5mg/10mg) for the treatment of adult patients with type two diabetes, especially the ones with comorbidities.

• Bharat Electronics Wins Rs 1,155 Crore Contracts, Shares End Flat
• Aurobindo Pharma Arm Gets USFDA Approval
• Gravita India Set to Acquire Recycling Facility in Europe; Shares Fall 
• Cleantech Startup Exposome Secured Funding of Rs 10 Crores from Colossa Ventures
• JSW Infrastructure to Raise Over Rs 5,000 Crore via QIP, Shares Up 6%

‘Zita D’ which contains Teneligliptin (20mg) andDapagliflozin (5 mg/10 mg). This medicine can be consumed by the patient once a day daily as per prescription, which helps to improve glycemic control and prevent complications in adult patients with type two diabetes, especially the ones with comorbidities, as per the statement said.